Home ::
Hormone Refractory Prostate News |
Hormone Refractory Prostate - Bing News
|
IMPORTANT: Bing News RSS feed has moved!
|
read more...
|
|
|
Radium-223 chloride (Alpharadin) halved risk of pathologic bone fracture and spinal cord compression and reduced the need for external beam radiation by a third in
read more...
|
|
Dendreon Announces Presentation of PROVENGE Data at the ASCO 2012 Genitourinary Cancers Symposium
|
PROVENGE Indication and Important Safety Information PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (
read more...
|
|
Dendreon Corp.'s Latest Developments: What They Mean
|
The FDA approved Provenge on April 29, 2010 to be used for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (
read more...
|
|
Novel Androgen Drug Gets 'Wow' in Advanced
|
Explain that an investigational androgen receptor antagonist boosts survival in castration-resistant
read more...
|
|
Bayer Initiates Expanded Access Program for Investigational Compound Radium-223 Chloride
|
LLC today announced that the U.S. Food and Drug Administration agreed that Bayer can proceed with its expanded access program to provide the investigational drug radium-223 chloride to patients diagnosed with castration-resistant
read more...
|
|
Dendreon Corporation : Dendreon Announces Presentation of PROVENGE Data at the ASCO 2012 Genitourinary Cancers Symposium
|
PROVENGE Indication and Important Safety Information PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (
read more...
|
|
|